Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases

• Main Authors: El Gammal AT (Author), Sturm JH (Author), Pinnschmidt HO (Author), Hofmann BT (Author), Bellon E (Author), et al (Author)
• Format: Book
• Published: International Journal of Clinical Endocrinology and Metabolism - Peertechz Publications, 2017-09-19.
• Subjects: Research Article
• Online Access: Connect to this object online.

<p><strong>Objectives:</strong> S100A8/A9 expression has been linked to carcinogenesis and inflammation.We hypothesized that S100A8/A9 protein serum levels are a useful stratification marker for patients with pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or chronic pancreatitis (CP). </p><p><strong>Methods:</strong> S100A8/A9 serum levels were analysed in PDAC, CP and IPMN patients and compared to S100A8/A9 healthy donor controls (HD) using ELISA. S100A8/A9 levels and clinical data were statistically analysed. </p><p><strong>Results:</strong> Out of134 patients included, 84 were diagnosed with PDAC (46%), 30 patients with IPMN (16%) and 20 patients with CP (11%), 50 patients were HD (27%). When compared to HD (343.3 ng/ml), S100A8/A9 serum concentration was elevated in PDAC (402.0 ng/ml, p = 0.001) and CP patients (426.51 ng/ml p < 0.001). Also, S100A8/A9 levels were elevated in PDAC compared to IPMN group (369.0 ng/ml p = 0.026) and in CP compared to IPMN group (p = 0.001). A multivariate model including age, gender, leukocyte levels, C-reactive protein (CrP), S100A8/A9 and CA 19-9 concentrations reported a diagnostic sensitivity of 74.8%.</p><p><strong>Conclusion:</strong> S100A8/A9 serum levels are increased in patients with PDAC, CP, and IPM might be useful to distinguish malignant and inflammatory diseases from normal and non-malignant pathological conditions.<br></p><br>